258 related articles for article (PubMed ID: 22457761)
1. Activation status of Wnt/ß-catenin signaling in normal and neoplastic breast tissues: relationship to HER2/neu expression in human and mouse.
Khalil S; Tan GA; Giri DD; Zhou XK; Howe LR
PLoS One; 2012; 7(3):e33421. PubMed ID: 22457761
[TBL] [Abstract][Full Text] [Related]
2. ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas.
Schroeder JA; Adriance MC; McConnell EJ; Thompson MC; Pockaj B; Gendler SJ
J Biol Chem; 2002 Jun; 277(25):22692-8. PubMed ID: 11950845
[TBL] [Abstract][Full Text] [Related]
3. Wnt pathway component LEF1 mediates tumor cell invasion and is expressed in human and murine breast cancers lacking ErbB2 (her-2/neu) overexpression.
Nguyen A; Rosner A; Milovanovic T; Hope C; Planutis K; Saha B; Chaiwun B; Lin F; Imam SA; Marsh JL; Holcombe RF
Int J Oncol; 2005 Oct; 27(4):949-56. PubMed ID: 16142310
[TBL] [Abstract][Full Text] [Related]
4. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome.
Khramtsov AI; Khramtsova GF; Tretiakova M; Huo D; Olopade OI; Goss KH
Am J Pathol; 2010 Jun; 176(6):2911-20. PubMed ID: 20395444
[TBL] [Abstract][Full Text] [Related]
5. Small molecule antagonists of the Wnt/β-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer.
Hallett RM; Kondratyev MK; Giacomelli AO; Nixon AM; Girgis-Gabardo A; Ilieva D; Hassell JA
PLoS One; 2012; 7(3):e33976. PubMed ID: 22470504
[TBL] [Abstract][Full Text] [Related]
6. Pea3 transcription factors and wnt1-induced mouse mammary neoplasia.
Baker R; Kent CV; Silbermann RA; Hassell JA; Young LJ; Howe LR
PLoS One; 2010 Jan; 5(1):e8854. PubMed ID: 20107508
[TBL] [Abstract][Full Text] [Related]
7. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
Prasad CP; Gupta SD; Rath G; Ralhan R
Oncology; 2007; 73(1-2):112-7. PubMed ID: 18337623
[TBL] [Abstract][Full Text] [Related]
8. Activation of the canonical Wnt/β-catenin pathway in ATF3-induced mammary tumors.
Yan L; Della Coletta L; Powell KL; Shen J; Thames H; Aldaz CM; MacLeod MC
PLoS One; 2011 Jan; 6(1):e16515. PubMed ID: 21304988
[TBL] [Abstract][Full Text] [Related]
9. GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.
Maric G; Annis MG; MacDonald PA; Russo C; Perkins D; Siwak DR; Mills GB; Siegel PM
Oncogene; 2019 Jun; 38(26):5294-5307. PubMed ID: 30914799
[TBL] [Abstract][Full Text] [Related]
10. Cytoplasmic localization of beta-catenin is a marker of poor outcome in breast cancer patients.
López-Knowles E; Zardawi SJ; McNeil CM; Millar EK; Crea P; Musgrove EA; Sutherland RL; O'Toole SA
Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):301-9. PubMed ID: 20056651
[TBL] [Abstract][Full Text] [Related]
11. β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
Geyer FC; Lacroix-Triki M; Savage K; Arnedos M; Lambros MB; MacKay A; Natrajan R; Reis-Filho JS
Mod Pathol; 2011 Feb; 24(2):209-31. PubMed ID: 21076461
[TBL] [Abstract][Full Text] [Related]
12. [Abnormal expression of beta-catenin and E-cadherin in Her2-positive breast cancer and its implications].
Niu LG; He JJ; Wang K; Zhang W; Zhou C
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2237-40. PubMed ID: 19923077
[TBL] [Abstract][Full Text] [Related]
13. Aberrant expression of β-catenin in invasive ductal breast carcinomas.
Abd El-Rehim D; Ali MM
J Egypt Natl Canc Inst; 2009 Jun; 21(2):185-95. PubMed ID: 21057570
[TBL] [Abstract][Full Text] [Related]
14. MMTV-Wnt1 and -DeltaN89beta-catenin induce canonical signaling in distinct progenitors and differentially activate Hedgehog signaling within mammary tumors.
Teissedre B; Pinderhughes A; Incassati A; Hatsell SJ; Hiremath M; Cowin P
PLoS One; 2009; 4(2):e4537. PubMed ID: 19225568
[TBL] [Abstract][Full Text] [Related]
15. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
16. A Wnt-ow of opportunity: targeting the Wnt/beta-catenin pathway in breast cancer.
Prosperi JR; Goss KH
Curr Drug Targets; 2010 Sep; 11(9):1074-88. PubMed ID: 20545611
[TBL] [Abstract][Full Text] [Related]
17. LGR5 overexpression confers poor relapse-free survival in breast cancer patients.
Hou MF; Chen PM; Chu PY
BMC Cancer; 2018 Feb; 18(1):219. PubMed ID: 29471794
[TBL] [Abstract][Full Text] [Related]
18. CD49f and CD61 identify Her2/neu-induced mammary tumor-initiating cells that are potentially derived from luminal progenitors and maintained by the integrin-TGFβ signaling.
Lo PK; Kanojia D; Liu X; Singh UP; Berger FG; Wang Q; Chen H
Oncogene; 2012 May; 31(21):2614-26. PubMed ID: 21996747
[TBL] [Abstract][Full Text] [Related]
19. Expression of frizzled-related protein and Wnt-signalling molecules in invasive human breast tumours.
Wong SC; Lo SF; Lee KC; Yam JW; Chan JK; Wendy Hsiao WL
J Pathol; 2002 Feb; 196(2):145-53. PubMed ID: 11793365
[TBL] [Abstract][Full Text] [Related]
20. SOX9 regulates low density lipoprotein receptor-related protein 6 (LRP6) and T-cell factor 4 (TCF4) expression and Wnt/β-catenin activation in breast cancer.
Wang H; He L; Ma F; Regan MM; Balk SP; Richardson AL; Yuan X
J Biol Chem; 2013 Mar; 288(9):6478-87. PubMed ID: 23306204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
